Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here are three stocks where you should be greedy instead of fearful.
Palantir Technologies (PLTR)
Consensus Price Target: $191.68 (10.3% implied return)
Named after the all-seeing stones in "Lord of the Rings," Palantir Technologies (NASDAQ: PLTR) develops software platforms that help government agencies and enterprises integrate, analyze, and operationalize their data for decision-making.
Why Should You Buy PLTR?
- Average billings growth of 76.7% over the last year enhances its liquidity and shows there is steady demand for its products
- User-friendly software enables clients to ramp up spending quickly, leading to the speedy recovery of customer acquisition costs
- Robust free cash flow margin of 56.5% gives it many options for capital deployment
At $173.83 per share, Palantir Technologies trades at 44.2x forward price-to-sales. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
AbbVie (ABBV)
Consensus Price Target: $276.59 (5.5% implied return)
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
Why Does ABBV Stand Out?
- Unparalleled scale of $64.39 billion in revenue gives it negotiating leverage and staying power in an industry with high barriers to entry
- Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
- ROIC punches in at 18.6%, illustrating management’s expertise in identifying profitable investments
AbbVie is trading at $262.20 per share, or 17.6x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Chevron (CVX)
Consensus Price Target: $217.88 (5.9% implied return)
Operating everything from deepwater drilling rigs to corner gas stations, Chevron (NYSE: CVX) explores for, produces, and transports crude oil and natural gas, then refines that crude oil into gasoline, diesel, and other petroleum products.
Why Are We Fans of CVX?
- Annual revenue growth of 6.3% over the past ten years was outstanding, reflecting market share gains this cycle
- Unparalleled revenue scale of $215.3 billion gives it advantageous pricing and terms with suppliers
- Free cash flow generation is better than most peers and allows it to explore new investment opportunities
Chevron’s stock price of $205.73 implies a valuation ratio of 13.3x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
